Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 242-247

  Bojang, Kalifa ^a   Milligan, Paul ^b   Pinder, Margaret ^a   Doherty, Tom ^b   Leach, Amanda ^c   Ofori Anyinam, Opokua ^c   Lievens, Marc ^c   Kester, Kent ^d   Schaecher, Kurt ^d   Ballou, W Ripley ^e   Cohen, Joe ^c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

AS02 adjuvant system; Five year follow up; Long term persistence of anti HBs; Malaria vaccine; RTS,S

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; PRE ERYTHROCYTIC MALARIA VACCINE; RABIES VACCINE; RTS,S ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATALITY; GAMBIA; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALARIA; MALE; MENTAL DISEASE; PARASITE IMMUNITY; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TUBERCULOSIS;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENDEMIC DISEASES; FOLLOW-UP STUDIES; GAMBIA; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; RABIES VACCINES; YOUNG ADULT;

EID: 70349485373     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7050     Document Type: Article

References (14)

1. Breman JG. The ears of the hippopotamus: manifestations, determinants and estimates of the malaria burden. Am J Trop Med Hyg 2001; 64:1-11.
2. WHO. http:/www.who.int/mediacentre/news/statements/2004/statement6/en. World Health Organisation, Geneva 2004.
3. Garçon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003; 2:231-8.
4. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-34.
5. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S/AS02 malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012-8.
6. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the RTS,S/AS02D vaccine against Plasmodium falciparum infection in infants. A phase I/IIb trial in a highly endemic area in Mozambique. Lancet 2007; 370:1543-51.
7. Ratcliffe AA, Hill AG, Gomez P, Walraven G. Farafenni DSS, The Gambia. In: Population and Health in Developing Countries. Ottawa: IDRC, 2002. www.idrc.ca/en/ev-43025-201-1-DO_TOPIC.html.
8. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 2004; 364:1411-20.
9. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999; 18:57-67.
10. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995; 13:443-7.
11. Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet 1984; 2:458.
12. Westmoreland D, Player V, Heap DC, Hammond A. Immunization against hepatitis B - what can we expect? Epid Infect 1990; 104:499-509.
13. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr5516a1.htm.
14. Greenwood BM, Armstrong JRM. Comparison of two simple methods for determining malaria parasite density. Trans Royal Society of Trop Med Hyg 1991; 85:186-8.